Oragenics Obtains U.S. Patent for IVIAT
Published October 17, 2011
Oragenics, Inc., Tampa, FL, has been issued patent No. 8,034,571 from the U.S. Patent and Trademark office for In Vivo Induced Antigen Technology (IVIAT). This platform technology is a novel approach for studying microbial pathogenesis that identifies genes of a pathogenic organism, which are differentially expressed during an actual human infection. IVIAT can be applied to all pathogenic bacteria, yeasts and parasites to rapidly identify proteins that are expressed when a pathogen infects a human. Such proteins are excellent targets for medical diagnostics and therapeutic strategies.